Categories: Artificial IntelligenceDataDesignDevelopmentFinTechPlatform
Targeting escape mutations in hematological cancers with first and best in class medicines.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 28.03.2025 | Lomond Therapeutics Raises $20 Million |
DOVER, DE, Lomond Therapeutics Holdings, a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, announced $20 m... |
| - | Lomond Therapeutics | “Targeting escape mutations in hematological cancers with first and best in class medicines.” |
Reviews 0
